非酒精性脂肪性肝病:调节肠道菌群以改善病情严重程度?
该综述探讨通过调节肠道菌群和肠-肝轴治疗非酒精性脂肪性肝病(NAFLD)。临床指南推荐减重7%-10%以改善NAFLD特征,但该目标难以普及。文章讨论益生菌、益生元、合生元、粪菌移植、多酚、特定饮食和运动干预如何改变菌群特征并改善结局;除益生菌已有随机对照试验外,多数治疗仅在动物中研究,疗效尚需人体验证。
要点
- 临床指南推荐减重7%-10%以改善NAFLD特征,但并非所有患者都能轻易达到。
- 益生菌已有随机对照试验,而多数菌群调节疗法仅在动物中研究。
- 益生菌、益生元、合生元、粪菌移植、多酚、饮食和运动可改变菌群特征并改善NAFLD结局。
核心结论
- 调节肠道菌群和肠-肝轴是改善NAFLD的潜在治疗策略,但多数疗法疗效尚需人体研究确认。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 益生菌、益生元、合生元、粪菌移植、多酚、特定饮食和运动干预可改变肠道菌群特征并改善NAFLD结局。
- 除益生菌已在人体随机对照试验中测试外,大多数潜在疗法仅在动物中研究。
关键数值与推荐
- 临床指南推荐减重7%-10%以改善NAFLD特征。
临床怎么用
- 益生菌已有随机对照试验证据,可考虑用于NAFLD辅助治疗;其他菌群调节疗法需等待人体研究验证。
局限性
- 大多数潜在疗法仅在动物中研究,疗效尚未在人体中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gut microbiota plays a role in the pathophysiology of metabolic diseases, which include nonalcoholic fatty liver diseases, through the gut-liver axis. To date, clinical guidelines recommend a weight loss goal of 7%-10% to improve features of nonalcoholic fatty liver diseases. Because this target is not easily achieved by all patients, alternative therapeutic options are currently being evaluated. This review focuses on therapeutics that aim to modulate the gut microbiota and the gut-liver axis. We discuss how probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets, and exercise interventions have been found to modify gut microbiota signatures; improve nonalcoholic fatty liver disease outcomes; and detail, when available, the different mechanisms by which these beneficial outcomes might occur. Apart from probiotics that have already been tested in human randomized controlled trials, most of these potential therapeutics have been studied in animals. Their efficacy still warrants confirmation in humans using appropriate design.
引用
- Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, et al. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology. 2020. PMID: 32044317. doi:10.1053/j.gastro.2020.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。